Skip to main content
. 2019 May 30;20(11):2674. doi: 10.3390/ijms20112674
cfDNA Cell-free DNA
CNI Copy number instability
CSC Cancer stem cells
CT scan Computed-tomography scanner
CTLA-4 Cytotoxic T-lymphocyte-associated antigen 4
ECOG Eastern cooperative oncology group
Fc Crystallizable fragment
FcR Crystallizable fragment receptor
HNSCC Head and neck squamous cell carcinoma
ICI Immune checkpoint inhibitor
iRECIST Immune response-evaluation criteria in solid tumors
irRC Immune-related response criteria
irRECIST Immune-related response-evaluation criteria in solid tumors
NGS Next-generation sequencing
NSCLC Non-small-cell lung cancer
OS Overall survival
PD-1 Programmed cell death protein 1
PD-L1 Programmed cell death ligand 1
PD-L2 Programmed cell death ligand 2
RECIST Response-evaluation criteria in solid tumors
TAM Tumor-associated macrophage
TGK Tumor growth kinetics
TGR Tumor growth rate
TILs Tumor-infiltrating T lymphocytes
Tregs Regulatory T-cells
TTF Time to treatment failure
uPD Unconfirmed progressive disease